Ono Pharmaceutical (OPHLF) Projected to Post Earnings on Wednesday

Ono Pharmaceutical (OTCMKTS:OPHLF) is projected to post its results before the market opens on Wednesday, October 28th. Analysts expect the company to post earnings of $0.26 per share and revenue of $728.39 million for the quarter.

Ono Pharmaceutical Price Performance

Shares of OTCMKTS:OPHLF opened at $15.16 on Wednesday. The company has a market cap of $7.12 billion, a price-to-earnings ratio of 13.42 and a beta of 0.38. The firm’s 50-day simple moving average is $15.11 and its 200-day simple moving average is $14.68. The company has a quick ratio of 2.86, a current ratio of 3.28 and a debt-to-equity ratio of 0.08. Ono Pharmaceutical has a fifty-two week low of $11.08 and a fifty-two week high of $18.67.

Analysts Set New Price Targets

Separately, Zacks Research cut shares of Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 4th. One research analyst has rated the stock with a Hold rating. According to MarketBeat.com, Ono Pharmaceutical has an average rating of “Hold”.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines. Its primary therapeutic areas include oncology, immunology, neurology and other specialty-care fields. The company develops medicines internally and also works with research institutions and global pharmaceutical partners.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer.